Michalska-Bańkowska Anna, Wcisło-Dziadecka Dominika, Grabarek Beniamin, Brzezińska-Wcisło Ligia, Mazurek Urszula, Salwowska Natalia, Bańkowski Mirosław
Chair and Department of Dermatology, School of Medicine, Medical University of Silesia, Katowice, Poland.
Department of Skin Structural Studies, Chair of Cosmetology, School of Pharmacy with Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Poland.
Postepy Dermatol Alergol. 2018 Oct;35(5):502-509. doi: 10.5114/ada.2018.77242. Epub 2018 Jul 19.
Psoriasis is a chronic, immunologic, multi-factor inflammatory skin disease, strongly associated with a higher level of a number of cytokines, such as isoforms of transforming growth factor β (TGF-β1-3) and its receptors (TGF-βRI-III). One of the most popular and important drugs used to treat this disease is cyclosporin A (CsA).
The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-β isoforms and receptors of the cytokine TGF-βRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy. It made an attempt to determine the usefulness of testing mRNA expression of β- and its receptors β as the supplementary molecular markers of lost sensitivity to the medicine.
The study group consisted of 32 patients with psoriasis (20 men and 12 women) treated with cyclosporin A. The changes in expression patterns of β and β were performed by real-time quantitative reverse transcription PCR (RTqPCR).
The expression of β and β were detected in the whole period of therapy with CsA. Changes in transcriptional activities of β and β during pharmacotherapy were observed. Differences in the expression of these genes were found before and after 42 and 84 days of using CsA.
The changes in expression profiles of β and β during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine.
银屑病是一种慢性、免疫性、多因素炎症性皮肤病，与多种细胞因子水平升高密切相关，如转化生长因子β（TGF-β1-3）及其受体（TGF-βRI-III）的亚型。用于治疗该疾病的最常用且重要的药物之一是环孢素A（CsA）。
本研究的目的是在对环孢素A治疗效果进行为期84天的观察期间，调查银屑病患者中编码转化生长因子（TGF）-β亚型和细胞因子TGF-βRs受体的基因表达情况。试图确定检测β及其受体β的mRNA表达作为对药物敏感性丧失的补充分子标志物的实用性。
研究组由32例接受环孢素A治疗的银屑病患者组成（20名男性和12名女性）。通过实时定量逆转录PCR（RTqPCR）检测β和β表达模式的变化。
在CsA治疗的整个期间均检测到β和β的表达。观察到药物治疗期间β和β转录活性的变化。在使用CsA 42天和84天前后发现这些基因表达存在差异。
CsA治疗期间β和β表达谱的变化可能是对药物敏感性丧失的有用分子标志物。
